All Stories

  1. Cyclophosphamide, fluorouracil and low-dose interleukin-2 and salvage combination chemotherapy in advanced cutaneous squamous cell carcinoma

    Article • Journal of Cancer Metastasis and Treatment, June 2020, OAE Publishing

    Giovanni Lo Re

  2. Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study

    Article • Cytokine, April 2020, Elsevier

    Giovanni Lo Re

  3. Importance of physical activity in maintaining disease stabilization in pancreatic cancer

    Article • Journal of Cancer Metastasis and Treatment, December 2019, OAE Publishing

    Giovanni Lo Re

  4. Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy

    Article • Minerva Urologica e Nefrologica, October 2019, Edizioni Minerva Medica

    Giovanni Lo Re

  5. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

    Article • Journal of Translational Medicine, August 2019, Springer Science + Business Media

    Giovanni Lo Re

  6. Chemo-immunotherapy as salvage therapy of advanced GIST

    Article • Surgical Case Reports, June 2019, Science Repository OU

    Giovanni Lo Re

  7. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine‐Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

    Article • The Oncologist, January 2019, Wiley

    Giovanni Lo Re

  8. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

    Article • BJU International, July 2018, Wiley

    Giovanni Lo Re, Dr Sebastiano Buti

  9. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy

    Article • PLoS ONE, July 2018, PLOS

    Giovanni Lo Re

  10. Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program

    Article • Future Oncology, June 2018, Future Medicine

    Giovanni Lo Re, Dr Sebastiano Buti

  11. Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience

    Article • Cytokine, June 2018, Elsevier

    Giovanni Lo Re

  12. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype

    Article • International Journal of Molecular Sciences, December 2017, MDPI AG

    Giovanni Lo Re, Fabio Puglisi

  13. Cyclophosphamide with (+)/without (-) fluorouracil followed by subcutaneous or intravenous interleukin-2 in solid tumors: An off-label experience.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  14. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  15. Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)- based third line treatment: Final results from a multicenter Italian study.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  16. Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  17. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial

    Article • Gynecologic Oncology, February 2017, Elsevier

    Giovanni Lo Re

  18. Analysis of factors affecting survival in patients with lung metastases from colorectal cancer who underwent VATS-assisted surgical excision

    Article • European Journal of Cancer, February 2017, Elsevier

    Giovanni Lo Re

  19. Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

    Article • Cancer Medicine, October 2016, Wiley

    Giovanni Lo Re

  20. Epidermotropic progression of melanoma during therapy with dabrafenib and trametinib

    Article • Journal of the American Academy of Dermatology, October 2016, Elsevier

    Giovanni Lo Re

  21. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

    Article • Annals of Oncology, October 2016, Elsevier

    Giovanni Lo Re

  22. Polymorphism of CDH1 Promoter Is a Predictor of Clinical Outcome in Patients with Metastatic Gastric Cancer Treated with chemotherapy

    Article • Annals of Oncology, September 2016, Elsevier

    Giovanni Lo Re

  23. Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  24. Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey

    Article • Clinical Genitourinary Cancer, April 2016, Elsevier

    Giovanni Lo Re

  25. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer

    Article • Future Oncology, February 2016, Future Medicine

    Giovanni Lo Re, GAETANO FACCHINI

  26. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme

    Article • Clinical Genitourinary Cancer, February 2016, Elsevier

    Giovanni Lo Re

  27. Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminar...

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI, Giovanni Lo Re

  28. Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?

    Article • Journal of Clinical Oncology, January 2016, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  29. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients

    Article • Future Oncology, November 2015, Future Medicine

    Dr vincenza conteduca, Giovanni Lo Re

  30. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial

    Article • Annals of Oncology, October 2015, Elsevier

    Giovanni Lo Re

  31. Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)

    Article • Annals of Oncology, October 2015, Elsevier

    Giovanni Lo Re

  32. What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment

    Article • Oncotarget, September 2015, Impact Journals, LLC

    Giovanni Lo Re

  33. 2334 Nab Paclitaxel (Nab-P) and Gemcitabine (G) as first line chemotherapy (CT) in advanced pancreatic cancer (APDAC) patients (pts): An Italian “real life” study

    Article • European Journal of Cancer, September 2015, Elsevier

    Giovanni Lo Re

  34. 2045 Serum vascular endothelial growth factor (VEGF) and metalloproteinase-7 (MMP7) as prognostic marker in patients with colorectal cancer and liver metastases

    Article • European Journal of Cancer, September 2015, Elsevier

    Giovanni Lo Re

  35. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature

    Article • Clinical Genitourinary Cancer, August 2015, Elsevier

    Giovanni Lo Re

  36. Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

    Article • International Journal of Cancer, July 2015, Wiley

    Giovanni Lo Re

  37. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

    Article • European Urology, July 2015, Elsevier

    GAETANO FACCHINI, Giovanni Lo Re

  38. Clinical outcomes in a contemporary series of “young” patients with castration-resistant prostate cancer who were 60 years and younger

    Article • Urologic Oncology Seminars and Original Investigations, June 2015, Elsevier

    Giovanni Lo Re

  39. Corrigendum

    Article • Future Oncology, June 2015, Future Medicine

    Dr Sebastiano Buti, GAETANO FACCHINI, Giovanni Lo Re

  40. Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  41. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial.

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  42. Visceral disease site to predict clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA): Results of the Italian compassionate use named patient program (NPP).

    Article • Journal of Clinical Oncology, May 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  43. Soluble serum Fas as a biomarker of early detection of bone or liver metastases in women with advanced breast cancer. A preliminary case-control study

    Article • Annals of Oncology, May 2015, Elsevier

    Giovanni Lo Re

  44. Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

    Article • Oncotarget, March 2015, Impact Journals, LLC

    Giovanni Lo Re

  45. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

    Article • Future Oncology, March 2015, Future Medicine

    GAETANO FACCHINI, Dr Sebastiano Buti, Giovanni Lo Re

  46. Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multic...

    Article • Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  47. Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.

    Article • Journal of Clinical Oncology, March 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  48. Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.

    Article • Journal of Clinical Oncology, January 2015, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  49. Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial

    Article • Oncology, January 2015, Karger Publishers

    Giovanni Lo Re

  50. Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications

    Article • Cancer Biology & Therapy, October 2014, Taylor & Francis

    Giovanni Lo Re

  51. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme

    Article • BJU International, October 2014, Wiley

    Giovanni Lo Re

  52. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

    Article • Targeted Oncology, September 2014, Springer Science + Business Media

    Dr Sebastiano Buti, Giovanni Lo Re

  53. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

    Article • Future Oncology, August 2014, Future Medicine

    Giovanni Lo Re

  54. Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis

    Article • Clinical Genitourinary Cancer, June 2014, Elsevier

    Giovanni Lo Re

  55. Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  56. Offlabel nab-paclitaxel: Gemcitabine chemotherapy in advanced pancreatic cancer—A monoinstitutional experience.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  57. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

    Article • Annals of Oncology, April 2014, Oxford University Press (OUP)

    Giovanni Lo Re, Prof. Emanuele Zucca

  58. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer

    Article • Journal of Geriatric Oncology, April 2014, Elsevier

    Giovanni Lo Re

  59. Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).

    Article • Journal of Clinical Oncology, February 2014, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  60. Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.

    Article • Journal of Clinical Oncology, February 2014, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  61. Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.

    Article • Journal of Clinical Oncology, February 2014, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  62. Comment on “Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results”: Will there be clinical implications in the future?

    Article • European Journal of Radiology, September 2013, Elsevier

    Giovanni Lo Re

  63. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

    Article • Expert Review of Anticancer Therapy, June 2013, Taylor & Francis

    Dr Matteo Santoni, Dr Michele Milella, MICHELE DE TURSI, Giovanni Lo Re

  64. Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    GAETANO FACCHINI, Giovanni Lo Re

  65. Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  66. Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  67. Prognostic Significance of Epidermal Growth Factor Receptor Overexpression and Chromosome 7 Polysomy in Clear Cell Renal Cell Carcinoma

    Article • Annals of Oncology, September 2012, Elsevier

    Giovanni Lo Re

  68. Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients

    Article • International Journal of Clinical Oncology, June 2012, Springer Science + Business Media

    Giovanni Lo Re

  69. Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel®(MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR)

    Article • April 2012, American Association for Cancer Research (AACR)

    Giovanni Lo Re

  70. 323 Vascular Endothelial Growth Factor as Prognostic Factor in Patients with Breast Cancer. a Multicentric Long-term Follow up Study

    Article • European Journal of Cancer, March 2012, Elsevier

    Giovanni Lo Re

  71. Interleukin-2 (IL-2) chrono-infusion (CHI) in metastatic renal cell carcinoma (mRCC): A phase I/II study.

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  72. Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC) (HOPLITE trial).

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  73. Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer.

    Article • Journal of Clinical Oncology, February 2012, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  74. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

    Article • European Journal of Cancer, February 2012, Elsevier

    Giovanni Lo Re

  75. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era

    Article • Journal of Neuro-Oncology, October 2011, Springer Science + Business Media

    GAETANO FACCHINI, Giovanni Lo Re

  76. 7059 POSTER Incidence and Outcomes of Brain and Meningeal Metastases (BMm) in Patients With Castration-resistant Prostate Cancer (CRPC) in the Era of Docetaxel (DOC)

    Article • European Journal of Cancer, September 2011, Elsevier

    GAETANO FACCHINI, Giovanni Lo Re

  77. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases

    Article • BJU International, May 2011, Wiley

    Giovanni Lo Re

  78. Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study

    Article • Journal of Immunotherapy, September 2010, Wolters Kluwer Health

    Dr Sebastiano Buti, Giovanni Lo Re

  79. Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory ...

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  80. Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

    Article • Journal of Clinical Oncology, February 2010, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  81. A phase II noncomparative study of neoadjuvant (NA) chemohormone therapy (CHT), radical prostatectomy (RP), and postoperative radiotherapy (RT) in locally advanced (LA) high-risk prostate cancer (HRPC): A monoinstitutional 6-year experience with two NA...

    Article • Journal of Clinical Oncology, May 2009, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  82. Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group ...

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  83. Gemcitabine (G) and epirubicin (E) combination, in platinum-resistant or refractory advanced ovarian cancer (PROC) patients: Results of a multicentric phase II trial

    Article • Journal of Clinical Oncology, May 2008, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  84. SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS

    Article • The Journal of Urology, April 2008, Wolters Kluwer Health

    Giovanni Lo Re

  85. Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor

    Article • European Urology, November 2006, Elsevier

    Giovanni Lo Re

  86. Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of ...

    Article • Journal of Clinical Oncology, August 2006, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  87. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients

    Article • European Journal of Cancer, July 2003, Elsevier

    Giovanni Lo Re

  88. Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial

    Article • Journal of Clinical Oncology, March 2002, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  89. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer

    Article • Lung Cancer, December 2001, Elsevier

    Giovanni Lo Re

  90. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.

    Article • Journal of Clinical Oncology, April 1997, American Society of Clinical Oncology (ASCO)

    Giovanni Lo Re

  91. Multidrug Chemotherapy in the Treatment of Non-Elderly Patients with Hormone-Refractory Prostatic Carcinoma

    Article • European Urology, January 1996, Elsevier

    Giovanni Lo Re

  92. Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients

    Article • European Journal of Cancer, January 1994, Elsevier

    Giovanni Lo Re

  93. The Aged Patient with Lung Cancer

    Article • Drugs & Aging, January 1994, Springer Science + Business Media

    Giovanni Lo Re

  94. Buserelin T reatment of Advanced Prostatic Carcinoma: Prognostic Factor Analysis

    Article • European Urology, January 1992, Elsevier

    Giovanni Lo Re

  95. Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer

    Article • Cancer Investigation, January 1991, Taylor & Francis

    Giovanni Lo Re

  96. Buserelin treatment of advanced prostatic cancer: A phase II study

    Article • Medical Oncology and Tumor Pharmacotherapy, December 1989, Springer Science + Business Media

    Giovanni Lo Re

  97. Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study

    Article • Cancer Chemotherapy and Pharmacology, February 1989, Springer Science + Business Media

    Giovanni Lo Re

  98. Low-Dose Aminoglutethimide Plus Steroid Replacement in Advanced Breast Cancer Patients Resistant to Conventional Therapies

    Article • Cancer Investigation, January 1989, Taylor & Francis

    Giovanni Lo Re

  99. Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

    Article • Cancer Investigation, January 1988, Taylor & Francis

    Giovanni Lo Re

  100. Intermittent pelvic arterial infusion with peptichemio, doxorubicin, and cisplatin for locally advanced and recurrent carcinoma of the uterine cervix

    Article • Cancer, July 1987, Wiley

    Giovanni Lo Re

  101. Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: A phase II study

    Article • European Journal of Cancer and Clinical Oncology, June 1987, Elsevier

    Giovanni Lo Re

  102. Phase II Study of Five-Day Continuous Infusion of Vinblastine in Patients With Metastatic Renal-Cell Carcinoma

    Article • American Journal of Clinical Oncology, June 1987, Wolters Kluwer Health

    Giovanni Lo Re

  103. Combination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract

    Article • European Journal of Cancer and Clinical Oncology, December 1986, Elsevier

    Giovanni Lo Re